{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:07:30Z","timestamp":1778897250915,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["202403021211142"],"award-info":[{"award-number":["202403021211142"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["20210302124692"],"award-info":[{"award-number":["20210302124692"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["20210302123273"],"award-info":[{"award-number":["20210302123273"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017949","name":"Health Commission of Shanxi Province","doi-asserted-by":"publisher","award":["2023025"],"award-info":[{"award-number":["2023025"]}],"id":[{"id":"10.13039\/100017949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017949","name":"Health Commission of Shanxi Province","doi-asserted-by":"publisher","award":["2019053"],"award-info":[{"award-number":["2019053"]}],"id":[{"id":"10.13039\/100017949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.peptides.2026.171485","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:51:56Z","timestamp":1774425116000},"page":"171485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neuroprotective effects of GLP-2 and a GLP-2\/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease"],"prefix":"10.1016","volume":"197","author":[{"given":"Peng","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZhaoNa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XiaoQiang","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HuiZhong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WanDa","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TianYi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.peptides.2026.171485_bib1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s40263-018-0548-y","article-title":"Drug repurposing in Parkinson's disease","volume":"32","author":"Athauda","year":"2018","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.peptides.2026.171485_bib2","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1093\/brain\/awad227","article-title":"Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit","volume":"146","author":"Belloso-Iguerategui","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.peptides.2026.171485_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2018.03.024","article-title":"DA5-CH, a novel GLP-1\/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP\/PS1 mouse model of Alzheimer's disease","volume":"827","author":"Cao","year":"2018","journal-title":"Eur. J. Pharm."},{"issue":"17","key":"10.1016\/j.peptides.2026.171485_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179583","article-title":"Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.peptides.2026.171485_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177972","article-title":"The novel GLP-1 \/ GIP dual agonist DA3-CH is more effective than liraglutide in the MPTP mouse model of Parkinson's disease","volume":"1003","author":"Feng","year":"2025","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.peptides.2026.171485_bib6","article-title":"Parkinson's disease and systemic inflammation","volume":"2011","author":"Ferrari","year":"2011","journal-title":"Park. Dis."},{"key":"10.1016\/j.peptides.2026.171485_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106058","article-title":"GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment","volume":"176","author":"Gabe","year":"2022","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.peptides.2026.171485_bib8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/BST20140016","article-title":"Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases","volume":"42","author":"Holscher","year":"2014","journal-title":"Biochem Soc. Trans."},{"key":"10.1016\/j.peptides.2026.171485_bib9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","article-title":"Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer\u2019s and Parkinson\u2019s disease models","volume":"136","author":"H\u00f6lscher","year":"2018","journal-title":"Neuropharmacol"},{"issue":"12","key":"10.1016\/j.peptides.2026.171485_bib10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40263-025-01226-z","volume":"39","author":"H\u00f6lscher","year":"2025","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.peptides.2026.171485_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/biom14070872","article-title":"Incretin-based multi-agonist peptides are neuroprotective and anti-inflammatory in cellular models of neurodegeneration","volume":"14","author":"Kopp","year":"2024","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.peptides.2026.171485_bib12","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1080\/21655979.2021.1958600","article-title":"Glucagon-like peptide (GLP) -2 improved colonizing bacteria and reduced severity of ulcerative colitis by enhancing the diversity and abundance of intestinal mucosa","volume":"12","author":"Li","year":"2021","journal-title":"Bioengineered"},{"key":"10.1016\/j.peptides.2026.171485_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neuropharm.2015.10.002","article-title":"Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model","volume":"101","author":"Li","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.peptides.2026.171485_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejphar.2016.11.050","article-title":"D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation","volume":"797","author":"Li","year":"2017","journal-title":"Eur. J. Pharm."},{"issue":"8","key":"10.1016\/j.peptides.2026.171485_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2231","article-title":"The GLP-1\/GIP dual-receptor agonist DA5-CH inhibits the NF-\u03baB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01.","volume":"11","author":"Lv","year":"2021","journal-title":"Brain Behav."},{"key":"10.1016\/j.peptides.2026.171485_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102118","article-title":"Glucose-dependent insulinotropic polypeptide (GIP).","volume":"95","author":"M\u00fcller","year":"2025","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2026.171485_bib17","article-title":"Evolution of initial pharmacologic treatment of newly diagnosed Parkinson's disease patients over a decade in Singapore","volume":"2020","author":"Neo","year":"2020","journal-title":"Park. Dis."},{"key":"10.1016\/j.peptides.2026.171485_bib18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev-pathol-011110-130242","article-title":"Parkinson's disease: genetics and pathogenesis","volume":"6","author":"Shulman","year":"2011","journal-title":"Annu Rev. Pathol."},{"issue":"1","key":"10.1016\/j.peptides.2026.171485_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12876-023-02716-4","article-title":"Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats","volume":"23","author":"Skarbaliene","year":"2023","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"10.1016\/j.peptides.2026.171485_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/a-1266-3263","article-title":"A GLP-2 analogue protects SH-SY5Y and neuro-2a cells against mitochondrial damage, autophagy impairments and apoptosis in a parkinson model","volume":"71","author":"Su","year":"2021","journal-title":"Drug Res."},{"issue":"4","key":"10.1016\/j.peptides.2026.171485_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041153","article-title":"Glucose-dependent insulinotropic polypeptide mitigates 6-OHDA-induced behavioral impairments in parkinsonian rats","volume":"19","author":"Yu","year":"2018","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.peptides.2026.171485_bib22","first-page":"523","article-title":"The novel dual GLP-1\/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of Parkinson's disease","volume":"10","author":"Zhang","year":"2020","journal-title":"J. Park. Dis."},{"issue":"2","key":"10.1016\/j.peptides.2026.171485_bib23","first-page":"529","article-title":"Neuroprotective effects of a GLP-2 analogue in the MPTP Parkinson's disease mouse model","volume":"11","author":"Zhang","year":"2021","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.peptides.2026.171485_bib24","article-title":"A dual GLP-1\/GIP receptor agonist is more effective than liraglutide in the A53T mouse model of Parkinson's disease","volume":"2023","author":"Zhang","year":"2023","journal-title":"Park. Dis."},{"key":"10.1016\/j.peptides.2026.171485_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170184","article-title":"GIP has neuroprotective effects in Alzheimer and Parkinson's disease models","volume":"125","author":"Zhang","year":"2020","journal-title":"Peptides"},{"issue":"6","key":"10.1016\/j.peptides.2026.171485_bib26","doi-asserted-by":"crossref","first-page":"nwae182","DOI":"10.1093\/nsr\/nwae182","article-title":"Lysophosphatidylcholine binds \u03b1-synuclein and prevents its pathological aggregation","volume":"11","author":"Zhao","year":"2024","journal-title":"Natl. Sci. Rev."}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978126000227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978126000227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:12:35Z","timestamp":1778893955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978126000227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":26,"alternative-id":["S0196978126000227"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2026.171485","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroprotective effects of GLP-2 and a GLP-2\/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2026.171485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"171485"}}